Skip to main content
Premium Trial:

Request an Annual Quote

Bruker's Q3 Revenues Rise 25 Percent; Tax-Law Changes Impact Bottom Line

NEW YORK (GenomeWeb News) - Bruker BioSciences today said third-quarter revenues increased 25 percent as R&D spending rose 24 percent and profit more than doubled.
Total receipts for the three months ended Sept. 30 increased 25 percent to $131.6 million from $104.9 million in the third quarter of 2006. Excluding the effects of foreign currency translation, third-quarter 2007 revenue increased by 20 percent, Bruker said.
Product revenue increased 25 percent to $115.2 million; service revenue increased 28 percent to $16.2 million; and "other" revenue fell 22 percent to $245,000.
The company did not offer revenue projections for the rest of the year.
R&D spending rose to $14.8 million from $11.9 million in the year-ago period.
Net profit rose to $8.7 million from $3 million in the year-ago period. The company said that income in the third quarter included a one-time tax benefit of $2.4 million related to a tax-law change in Germany that required a revaluation of Bruker’s deferred tax assets and liabilities.
Bruker held around $38.9 million in cash and cash equivalents, and short-term investments as of Sept. 30.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.